Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Balzarini

Showing results (401-410 of 563) with videos related to

Pageof 57
Sort By:
Nucleosides, Nucleotides & Nucleic Acids|September 21, 2001
Novel aryl substituted bicyclic furo nucleosides as extremely potent and selective anti-VZV agentsC McGuigan, H Barucki, A Carangio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1990
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenineH Egberink, M Borst, H Niphuis, et al.
Molecular Pharmacology|May 1, 1996
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidineJ Balzarini, H Pelemans, M J Pérez-Pérez, et al.
Molecular Pharmacology|January 1, 1993
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analoguesJ Balzarini, S Velazquez, A San-Felix, et al.
Journal of Medicinal Chemistry|October 10, 1998
Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replicationE Arranz, J A Díaz, S T Ingate, et al.
Antiviral Chemistry & Chemotherapy|July 20, 2000
Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activityA Martinez, A Esteban, A Castro, et al.
Biochemical Pharmacology|July 1, 1986
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivityD A Cooney, M Dalal, H Mitsuya, et al.
Journal of Medicinal Chemistry|April 29, 1994
An epimer of 5'-noraristeromycin and its antiviral propertiesS M Siddiqi, X Chen, S W Schneller, et al.
The Journal of Biological Chemistry|October 14, 1994
Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunitH Jonckheere, J M Taymans, J Balzarini, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1995
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)J Balzarini, M J Pérez-Pérez, S Vélazquez, et al.
Pageof 57

Showing results (401-410 of 563) with videos related to

Sort By:
Pageof 57
Nucleosides, Nucleotides & Nucleic Acids|September 21, 2001
Novel aryl substituted bicyclic furo nucleosides as extremely potent and selective anti-VZV agentsC McGuigan, H Barucki, A Carangio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1990
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenineH Egberink, M Borst, H Niphuis, et al.
Molecular Pharmacology|May 1, 1996
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidineJ Balzarini, H Pelemans, M J Pérez-Pérez, et al.
Molecular Pharmacology|January 1, 1993
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analoguesJ Balzarini, S Velazquez, A San-Felix, et al.
Journal of Medicinal Chemistry|October 10, 1998
Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replicationE Arranz, J A Díaz, S T Ingate, et al.
Antiviral Chemistry & Chemotherapy|July 20, 2000
Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activityA Martinez, A Esteban, A Castro, et al.
Biochemical Pharmacology|July 1, 1986
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivityD A Cooney, M Dalal, H Mitsuya, et al.
Journal of Medicinal Chemistry|April 29, 1994
An epimer of 5'-noraristeromycin and its antiviral propertiesS M Siddiqi, X Chen, S W Schneller, et al.
The Journal of Biological Chemistry|October 14, 1994
Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunitH Jonckheere, J M Taymans, J Balzarini, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1995
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)J Balzarini, M J Pérez-Pérez, S Vélazquez, et al.
Pageof 57